No Data
Wolfe Downgrades RAPT, but Still Sees "Immense" Upside Potential
Wolfe Research: Downgraded RAPT Therapeutics (RAPT.US) rating from superior to market to Peer Perform.
Wolfe Research: Downgraded RAPT Therapeutics (RAPT.US) rating from superior to market to Peer Perform.
Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform
RAPT Therapeutics (RAPT) has an average rating of outperform and price targets ranging from $4 to $33, according to analysts polled by Capital IQ.
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)
Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation
RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview